Phenylbutyrate Therapy for Maple Syrup Urine Disease (MSUD)
A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial of Phenylbutyrate in the Treatment of Maple Syrup Urine Disease
Sponsor: Brendan Lee
Listed as NCT01529060, this PHASE2/PHASE3 trial focuses on Maple Syrup Urine Disease and remains completed. Sponsored by Brendan Lee, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 5 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed
-
Feb 2019 — Apr 2019 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brendan Lee
For direct contact, visit the study record on ClinicalTrials.gov .